A review of the long-term protection after hepatitis A and B vaccination
- PMID: 17298912
- DOI: 10.1016/j.tmaid.2006.04.004
A review of the long-term protection after hepatitis A and B vaccination
Abstract
Vaccine-preventable viral hepatitis continues to be a cause of considerable morbidity and mortality: on worldwide basis, approximately 1.4 million cases of hepatitis A are reported every year. The true incidence, however, has been estimated to be 3-10 times higher. Regarding hepatitis B, more than a third of the world's population has been infected. The World Health Organization has estimated (2000) that there are 367 million chronic carriers of hepatitis B worldwide, and approximately 1 million deaths per year as a consequence of chronic complications and acute fulminant disease. Hepatitis B vaccines have been licensed since 1982, and hepatitis A vaccines since 1992. In 1996, a combined hepatitis A and B vaccine became available. An update on the long-term protection conferred by hepatitis A and hepatitis B vaccines as well as the combined hepatitis A and B vaccine is offered in this paper. Long-term efficacy and booster policy for hepatitis B vaccines have often been a topic of discussion. Based on current data and field experience there is, in general, no necessity for booster doses for fully vaccinated immunocompetent individuals. Long-term protection has been demonstrated by the rapid (5-7 days) development of anamnestic antibody responses among vaccinees who no longer have detectable anti-HBs. Anamnestic responses correlate with lymphoproliferative T-cell responses following challenge with hepatitis B vaccine. Furthermore, employing Spot-ELISA techniques, circulating B-cells were shown to be able to produce anti-HBs in vaccinees who lost their detectable antibodies. The accumulated data from a large number of studies indicate that despite antibody decline or loss, immune memory exhibits long-term persistence. There is somewhat less information available for hepatitis A vaccines, yet an increasing number of studies indicate that the findings for hepatitis B vaccines are also applicable to hepatitis A vaccines. The necessity to provide a booster dose was based on early projections of observed antibody levels. However, recent follow-up studies with up to 12 year observation, as well as studies employing mathematical models predict that following primary vaccination, antibodies will persist for at least 25 years. In addition, experimental studies confirm that vaccination against hepatitis A induces immunological memory. Therefore hepatitis A booster vaccination is presently considered as unnecessary in fully vaccinated individuals. The above findings are of importance in the context of administering combined hepatitis A and B vaccine for which similar long-term data have been observed. All available data on monovalent and combined hepatitis A and hepatitis B vaccines indicates that there is no support for a hepatitis A or hepatitis B booster when a complete primary vaccination course is offered to immunocompetent individuals.
Similar articles
-
Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents.Vaccine. 2007 Apr 20;25(16):3129-32. doi: 10.1016/j.vaccine.2007.01.045. Epub 2007 Jan 19. Vaccine. 2007. PMID: 17291637
-
[Vaccination against viral hepatitis A and B in adults aged over 40 years--antibody persistence and immune memory].Epidemiol Mikrobiol Imunol. 2011 Sep;60(3):99-108. Epidemiol Mikrobiol Imunol. 2011. PMID: 22132651 Clinical Trial. Czech.
-
[Studies on the status of immune memory after completion of hepatitis B vaccination].Zhonghua Liu Xing Bing Xue Za Zhi. 2007 Apr;28(4):319-21. Zhonghua Liu Xing Bing Xue Za Zhi. 2007. PMID: 17850693 Chinese.
-
Hepatitis A and B booster recommendations: implications for travelers.Clin Infect Dis. 2005 Oct 1;41(7):1020-6. doi: 10.1086/433182. Epub 2005 Aug 29. Clin Infect Dis. 2005. PMID: 16142669 Review.
-
A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine.Expert Rev Vaccines. 2004 Jun;3(3):249-67. doi: 10.1586/14760584.3.3.249. Expert Rev Vaccines. 2004. PMID: 15176942 Review.
Cited by
-
The Impact of Smoking on Long-Term Protection Following Hepatitis B Vaccination: A 24-Year Cohort Study.Viruses. 2024 Jul 16;16(7):1137. doi: 10.3390/v16071137. Viruses. 2024. PMID: 39066298 Free PMC article.
-
Attractive and healthy-looking male faces do not show higher immunoreactivity.Sci Rep. 2022 Nov 1;12(1):18432. doi: 10.1038/s41598-022-22866-x. Sci Rep. 2022. PMID: 36319732 Free PMC article.
-
Susceptibility to Vaccine-Preventable Diseases in Four Districts of Xaysomboun Province, Lao People's Democratic Republic.Vaccines (Basel). 2022 Mar 17;10(3):463. doi: 10.3390/vaccines10030463. Vaccines (Basel). 2022. PMID: 35335095 Free PMC article.
-
The prevalence of adaptive immunity to COVID-19 and reinfection after recovery - a comprehensive systematic review and meta-analysis.Pathog Glob Health. 2022 Jul;116(5):269-281. doi: 10.1080/20477724.2022.2029301. Epub 2022 Jan 31. Pathog Glob Health. 2022. PMID: 35099367 Free PMC article.
-
Predictive Markers of Immunogenicity and Efficacy for Human Vaccines.Vaccines (Basel). 2021 Jun 1;9(6):579. doi: 10.3390/vaccines9060579. Vaccines (Basel). 2021. PMID: 34205932 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical